Solid Biosciences Inc. Income Statement
SLDB|5 years of annual SEC 10-K data (FY2018-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Solid Biosciences Inc. reported $14M in revenue and $88M in net loss for FY2022. Its profit margin was -648.2% in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $13.6M | $0 | $0 | $0 | $0 |
| SG&A Expense | $21.6M | $24.6M | $17.7M | $15.0M | $5.5M |
| R&D Expense | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| Operating Income | -$88.4M | -$119.3M | -$75.7M | -$54.9M | -$25.6M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$88.3M | -$117.2M | -$74.8M | -$52.1M | -$21.5M |
| EPS (Basic) | -$25.50 | - | - | - | - |
| EPS (Diluted) | -$25.50 | -$2.91 | -$2.25 | -$2.88 | -$10.14 |
| Shares Outstanding | 7.4M | 84.9M | 46.0M | 35.4M | 0 |
| Operating Margin | -649.1% | - | - | - | - |
| Profit Margin | -648.2% | - | - | - | - |